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The efficacy of three SIVmac32H gp130 vaccines was compared in rhesus monkeys. Three rhesus monkeys were
each immunized over a period of 20 weeks with a total of 600 mg virion-derived gp130 oligomers (O-gp130) mixed with
keyhole limpet hemocyanin and emulsified with incomplete Freund’s adjuvant. Three other monkeys were infected with
5 1 108 PFU of vaccinia virus wild type (VV-wt) while three additional animals received an equivalent dose of VV
expressing the gp130 of SIVmac (VV-gp130). At Week 8, the two VV-wt animals received an additional immunization
with 100 mg O-gp130 each. All VV-infected animals then received booster immunizations at Weeks 12, 16, and 20 with
a total of 300 mg O-gp130 per animal. All animals along with two controls were challenged iv with 50 MID50 of T-cell-
grown SIVmac32H at Week 22. Four weeks after the challenge and thereafter, both controls and one animal from either
VV group were infected as demonstrated by polymerase chain reaction (PCR), virus isolation, and antibody response.
In contrast, all O-gp130 animals and one animal each from the VV-wt and the VV-gp130 group were completely protected
as shown by negative PCR and virus reisolation. One animal of the VV-gp130 group was partially protected, since it
remained virus isolation negative but became PCR positive. All protected animals did not develop a secondary antibody
response. Six months after the first challenge, the five completely protected animals were reimmunized twice 4 weeks
apart with a total of 200 mg O-gp130 per animal. Two weeks later, all animals were challenged with 5 MID50 of the
SIVmac32H/spI prepared from the spleen of an immunized, but unprotected SIV-infected rhesus monkey. After the
second challenge, all three control animals and one of the vaccinees became productively infected. In contrast, two
animals were completely protected, one from the former O-gp130 and one from the former VV-gp130 group. One animal
from the former VV-wt group was only DNA – PCR positive and thus partially protected. Therefore, immunization with
virion-derived gp130 oligomers of SIVmac32H can confer protection against the infection with T-cell-grown SIVmac32H
as well as the ex vivo isolate SIVmac32H/spI. q 1996 Academic Press, Inc.
Three types of animal models have been developed ments a protective immunity was induced with recom-
to examine potential AIDS vaccines. Chimpanzees are binant gp120 (12) and an immunization protocol includ-
infectable with HIV-1 (1), whereas macaques replicate ing vaccinia virus (VV) priming and boosting with a
simian immunodeficiency virus (SIV) (2) and HIV-2 (3). mixture of recombinant viral components (13). In the
However, only SIV-infected macaques develop a disease HIV-2 macaque model only one experiment with a sub-
comparable to human AIDS (4). Whole inactivated virus unit vaccine was published. Highly purified, virion-de-
(WIV), inactivated cell-bound antigen, detergent-treated rived gp130 oligomers induced a sterilizing immunity
virus, a split vaccine like Tween–ether (TE) extracts, and against the homologous challenge and a partial pro-
ISCOMs can protect macaques from infection by SIV and tection against a challenge with a heterologous, more
HIV-2 (5–8). Interestingly, WIV of HIV-1 was not protective replication-competent HIV-2 isolate (14). Additional
in chimpanzees (9). subunit vaccine trials were carried out in the SIV ma-
Subunit vaccines were tested in all three animal caque model. With an enriched, virion-derived but not
models. In early trials with chimpanzees protection purified monomeric gp130 preparation, 50% protection
could not be induced with virion-derived or recombi- was obtained against the homologous SIV infection
nant gp120 (10, 11). However, in subsequent experi- (15). In contrast immunity against primary infection
with SIVmac could not yet be achieved with recombi-
nant gp130 or gp160 (16 – 19). However, macaques1 To whom reprint requests should be addressed. Fax: (/49-551)
3851-184. were protected against an SIV challenge after priming
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with live recombinant VV expressing gp160 followed by
immunization with partially purified recombinant gp160
(20). Considering these reports, more clear-cut results
were desirable.
Here we report on a vaccine trial in nine rhesus ma-
caques (Macaca mulatta) immunized with purified, virion-
derived SIVmac32H gp130 oligomers. Three animals
were primed with VV wild type (VV-wt) and another three
with VV expressing the gp130 (VV-gp130). The prepara-
tion and in vivo titration of the SIVmac32H challenge
stock have been described (21). For preparation of the
SIVmac32H/spI, the spleen of an SIV-infected rhesus FIG. 1. Serological reactivity and CD4 binding specificity of SIV-
monkey (21) was homogenized, the homogenate was mac32H gp130 oligomers. 125I-labeled gp130 oligomers were analyzed
by SDS–PAGE and autoradiography after immunoprecipitation (A) withcleared by low-speed centrifugation, and the supernatant
various antisera obtained from rhesus monkey 1604, experimentallywas adjusted to a protein concentration of 5 mg/ml. For
infected with SIVmac251 (lane 1), from cynomolgus monkey 778 experi-in vivo titration, two rhesus monkeys per dose were inoc- mentally infected with HIV-2ben (lane 2), from two HIV-1 patients (lane
ulated with 1 ml of a 1002, 1003, or 1004 dilution of the 3 and 4) and a negative control serum (lane 5), as well as after
virus stock. Infection was monitored by polymerase chain immunoprecipitation with monoclonal antibodies directed against MHC
class I (lane 6), MHC class II (lane 7), b2-microglobulin (lane 8), andreaction (PCR) (22, 23), virus isolation (23), and antibody
OKT4 (lane 9). (B) 125I–gp130–CD4 complexes were immunoprecipi-response in an ELISA with recombinant SIVmac gp140
tated with the antiserum of monkey 1604 (lane 1), the monoclonal(rgp140) (24). Eight weeks after infection and thereafter, antibodies OKT4a (lane 2) and OKT4 (lane 4), and a negative control
all animals infected with the 1002 and 1003 dilutions were serum (lane 3).
PCR positive, virus could be isolated, and a primary im-
mune response had developed with the exception of one
animal in the 1003 group (data not shown). All animals gp130) were mixed with keyhole limpet hemocyanin (Cal-
biochem, La Jolla, CA) in a ratio of 1:3 and emulsified inof the 1004 group remained virus isolation negative and
did not develop a primary immune response despite be- incomplete Freund’s adjuvant. All animals were derived
from the DPZ breeding colony containing only monkeyscoming DNA–PCR positive (data not shown). Thus, 0.5
ml of a 1003 dilution of our SIVmac32H/spI virus stock of Indian origin. Three rhesus monkeys were immunized
intramuscularly five times at Weeks 0, 4, 8, 12, and 20contained 5 MID50 .
For the immunization experiments, the SIVmac32H with a single dose of 100 mg O-gp130 per animal. Three
other rhesus monkeys were infected by skin scarificationwas propagated in C8166 cells, harvested by differential
centrifugation, and the gp130 oligomers were purified by with 5 1 108 PFU of the live recombinant VV-gp130 of
SIVmacBK28 clone (kindly provided by Dr. A. Burny, Uni-a two-step procedure (25). The purity of the preparation
was demonstrated by radioimmunoprecipitation assays versity of Brussels, Belgium) at Weeks 0 and 8. At Weeks
12, 16, and 20 these animals were boosted with 100(RIPA) of 125I-labeled gp130 oligomers with different anti-
sera as well as monoclonal antibodies (MAB). As shown mg O-gp130 per dose. Two additional macaques were
infected with live VV-wt at 0 and 8 weeks and boostedin Fig. 1A, only the antiserum from SIVmac251-infected
rhesus monkey 1604 (lane 1) and the antiserum from HIV- in Weeks 8, 12, 16, and 20 with O-gp130, again with 100
mg per dose. At Week 22, all animals were challenged2ben-infected cynomolgous monkey 778 (lane 2) reacted
with the gp130 oligomers, but neither two HIV-1-specific with 50 MID50 of the T-cell-grown SIVmac32H. At the
time of the first challenge, all vaccinated animals hadhuman sera (lanes 3 and 4) nor a monkey control serum
(lane 5). Major contaminating proteins could not be de- generated high gp130 antibody titers during the immuni-
zation period (25). The gp130 titers of the O-gp130-immu-tected by MABs against HLA class I and II (lanes 6 and
7), b2-microglobulin (lane 8) and the CD4 molecule (lane nized animals ranged between 104 and 105 (Table 1) as
determined in an ELISA with rgp140 of SIVmac (24). The9). The gp130 oligomers still bound to CD4 (14) and thus
their structural integrity was retained (Fig. 1B). The highest anti-gp130 titers were obtained in the animals
primed with VV-gp130 and boosted with O-gp130. Theirgp130–CD4 complexes could be precipitated with the
antiserum from rhesus monkey 1604, infected with SIV- titers ranged between 103 and 106. However, the highest
virus neutralizing antibody titers (26) up to 104 had devel-mac251 (lane 1) and the anti-CD4 MAB OKT4 (lane 4).
Precipitates were not obtained with the MAB OKT4a di- oped in the O-gp130-immunized animals, whereas the
titers in the VV-gp130-primed animals ranged betweenrected against the binding site on the CD4 molecule of
the external glycoproteins of immunodeficiency viruses 0.8 1 102 and 3.2 1 102. The VV-wt animals developed
neither high gp130 binding titers nor neutralizing antibod-(lane 2) and a monkey control serum (lane 3).
For vaccine preparation, the gp130 oligomers (O- ies. In individual sera high neutralizing antibodies corre-
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TABLE 1
Immune Status before and Viral Activity of Rhesus Monkeys after the First Challenge with T-Cell-Grown SIVmac32H
Immune status before challenge Signs of infection after challenge
Animal SIV NAB titers Anti-gp130 T-cell profile CD4-binding Virus Antibody
no. immunogenea (Ig)b titers (Ig)c rationd (SI values) inhibition (%) PCR isolation response
Controls
1721 / / Primary
1744 / / Primary
Vaccinees
1698 gp130 3.7 5 — 70 0 0 —
1701 gp130 3.7 4 — 63 0 0 —
1715 gp130 4.0 5 — 94 0 0 —
1753 VVwt/gp130 1.9 3 4 5 / / Secondary
1763 VVwt/gp130 2.5 4 — 9 0 0 —
1729 VVgp130/gp130 2.2 6 8 49 / 0 —
1768 VVgp130/gp130 1.9 6 10 47 / / Secondary
1769 VVgp130/gp130 2.5 3 17 45 0 0 —
a gp130, virion-derived gp130; VVwt, vaccinia wild-type virus; VVgp130, vaccinia virus expressing SIV gp130.
b Nab, neutralizing serum antibodies measured in the MT-4 cell assay.
c Measured in ELISA using recombinant gp140 (Repligen) as antigen.
d rgp140 was used as antigen.
lated with strong CD4-binding inhibition determined as animals (1729) was only DNA–PCR positive but showed
neither a secondary immune response nor viremia (Tablepreviously described (27, 28). All sera of the O-gp130
group inhibited the CD4 binding by more than 50%, 1), indicating suppression of virus replication. Analysis
of the MHC class II alleles (30) of the animals revealedwhereas antisera from both VV-primed groups did not
(Table 1). None of the immunized animals developed no association to protection (data not shown).
About half a year later, the protected animals werecytotoxic T-lymphocytes (CTL; data not shown) at any
time. However, all VV-gp130-primed animals had devel- boosted twice 4 weeks apart with 100 mg O-gp130 per
dose. Two weeks later, the revaccinated animals andoped a moderate to high proliferative T-cell response
(29) with stimulation indices (SI) between 8 and 17, three naive controls were challenged with 5 MID50 of the
SIVmac32H/spI. At the time of challenge, all animals ofwhereas only 1 of the 2 VV-wt-primed animals exhibited
a low T-cell reactivity with a SI of about 4 (Table 1). The the former O-gp130 group again developed high neu-
tralizing antibody titers between 2.5 1 103 and 5 1 103,O-gp130 animals remained negative in this assay.
As measured by the gp130 ELISA after the challenge whereas both formerly VV-primed animals had devel-
oped intermediate neutralizing titers of about 0.6 1 103using gp130 oligomers as antigen (14, 28), all control
animals developed a primary immune response indicat- (Table 2). gp130 binding titers ranged between 104 and
105. Unlike the response at the time of the first challenge,ing virus replication (Table 1). In contrast, none of the
three O-gp130-immunized animals (1698, 1701, and high neutralizing antibody titers did not correlate with an
efficient serum CD4-binding inhibition (50%, Table 2).1715) exhibited a secondary immune response, indicat-
ing no SIVmac32H multiplication (Table 1). Respective Also in contrast to observations at the time of first chal-
lenge, at time of the second challenge only the animalsresults were obtained by virus reisolation and PCR analy-
sis. Whereas all control animals became viremic and of the former O-gp130 group had developed low to mod-
erate proliferative T-cell responses with SI values of 3 toPCR positive, the O-gp130 animals remained negative
(Table 1). Therefore the O-gp130 animals were protected 7, whereas the animals from both former VV-primed
groups remained negative (Table 2). After the secondagainst the infection with SIVmac32H. The VV-primed
animals responded more heterogenously. Whereas one challenge all three control animals, 1513, 1623, and 1546,
became infected. They exhibited a primary immune re-of the three VV-gp130 (1769)- and one of the two VV-wt-
primed animals (1763) showed no sign of SIVmac32H sponse and were positive in DNA–PCR (Table 2). How-
ever only two of the three control animals (1513 andinfection and were thus protected, one of the VV-gp130
(1768) and one of the VV-wt animals (1753) developed a 1623) became viremic. RNA–PCR was performed (31) to
detect a low-level virus replication of the control animalsecondary antibody response and became viremic and
PCR positive (Table 1). However, one of the VV-gp130 1546 negative in virus reisolation. All control animals
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TABLE 2
Immune Status before and Viral Activity of Rhesus Monkeys after the Second Challenge with SIVmac32H/spI
Immune status before challenge Signs of SIVmac32H infection after challenge
T-cell CD4- PCR
profile binding Plasma
Animal SIV Nab titers anti-gp130 rationd (SI inhibition Proviral Genomic p24 Virus Antibody
no. immunogena (Ig)b titers (Ig)c values) (%) DNA RNA antigen isolation response
Controls
1513 / / / / Primary
1546 / / 0 0 Primary
1623 / / / / Primary
Vacinees
1698 gp130 3.4 4 4 17 / / / / Secondary
1701 gp130 3.4 4 7 21 / / / / Secondary
1715 gp130 3.7 5 3 63 0 0 0 0 —
1763 VVwt/gp130 2.8 4 — 63 / 0 0 0 —
1769 VVgp130/gp130 2.8 4 — 60 0 0 0 0 —
a gp130, virion-derived gp130; VVwt, vaccinia wild-type virus; VVgp130, vaccinia virus expressing SIV gp130.
b Nab, neutralizing serum antibodies measured in the MT-4 cell assay.
c Measured in ELISA using recombinant gp140 (Repligen) as antigen.
d rgp140 was used as antigen.
were positive in RNA–PCR, indicating free virus particles (Fig. 2B, lanes 1 to 2). At the time of the second challenge,
the reactivity against cellular components of the immunein the plasma (Table 2). Two of the immunized animals
from the former O-gp130 group (1698 and 1701) also had sera, the MABs, as well as the antiserum from monkey
1604 was investigated by Western blot analysis with aall signs of SIVmac infection. They exhibited a secondary
immune response (Table 2) and were positive in virus pool of nonstimulated or stimulated PBMCs from different
reisolation and DNA– as well as RNA–PCR (Table 2).
However, two of the immunized animals, no. 1715 of the
former O-gp130 group and no. 1769 of the former VV-
gp130 group, showed no secondary immune response
and remained negative in virus isolation as well as DNA –
and RNA–PCR (Table 2). These two animals were thus
protected. The other animal from the former VV-wt group
(1763) was only DNA–PCR positive but remained nega-
tive for all other infection parameters (Table 2), indicating
suppression of virus replication. Again, a correlation of
protection to MHC class II alleles could not be detected
(data not shown).
Furthermore, RIPAs with extracts of 35S-labeled SIV-
mac32H-infected C8166 cells were performed to investi- FIG. 2. Immunological reactivity of the immune sera at time of first
gate the serum reactivities against cellular components challenge with a human T-cell line. C8166 cells, infected with SIV-
mac32H, were methabolically labeled and cell extracts were immuno-at the time of the first challenge. All immune sera precipi-
precipitated with the immune sera from the O-gp130 animals (A) 1698tated in addition to gp130 a faint band of 45 kDa (Fig.
(lane 1), 1701 (lane 2), and 1715 (lane 3), the control animals 1721 (lane2A, lanes 1 to 3, and Fig. 2C, lanes 1 to 5). The latter
4) and 1744 (lane 5), and with the monoclonal antibodies against MHC
band was not detected by the sera of the control animals class I (lane 6), MHC class II (lane 7), and OKT4 (lane 8). (B) As a
(lanes 4 and 5). However, a similar faint band was also positive and a negative control, immunoprecipitations were performed
with the antiserum of monkey 1604, eprimentally infected with SIV-recognized by the MAB against HLA class I (Fig. 2A, lane
mac251 (lane 1), and a serum from an uninfected animal (lane 2). (C)6, and Fig. 2C, lane 6) but not by all other MABs tested
Similarly, immunoprecipitations were carried out with the immune sera(Fig. 2A, lanes 7 to 8, and Fig. 2C, lanes 7 to 8). A very
of the VV-gp130 animals 1729 (lane 1), 1768 (lane 2), and 1769 (lane
faint band of 45 kDa was also precipitated in addition to 3), of the VV-wt animals 1763 (lane 4) and 1753 (lane 5), and the
the gp130 by the antiserum of the SIVmac251-infected monoclonal antibodies against MHC class I (lane 6), MHC class II
(lane 7), and OKT4 (lane 8).monkey 1604, but not by the negative monkey serum
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gp160 molecules were tested (18, 19). Again, in no case
could protection be obtained. Therefore, recombinant
monomeric gp130 or gp160 preparations are apparently
unsuitable as vaccines against SIV. This conclusion was
also confirmed by another recent study comparing whole
inactivated viral vaccines with different recombinant sub-
unit preparations (33). In this study four levels of resis-
tance to SIV infection were obtained: (i) no detectable
virus (sterilizing immunity), (ii) abortive infection (strong
immunity) characterized by virus or provirus detection
early after challenge, (iii) suppression of infection (incom-FIG. 3. Immunological reactivity of the immune sera at time of first
plete or partial immunity) defined by a terminated viremia,and second challenge. Virion-derived gp130 oligomers were iodinated
and immunoprecipitations were performed at the time of the first chal- declining of antibody titers after challenge and low provi-
lenge (A) with the immune sera of the O-gp130 animals 1715 (lane 1), rus load, or (iv) active infection (no immunity). Sterilizing
1701 (lane 2), and 1768 (lane 3), (B) with the immune sera of the VV- immunity was only obtained with whole inactivated virus.
gp130 animals 1729 (lane 1), 1753 (lane 2), and 1763 (lane 3), and the
A strong immunity was induced only in two animals, oneVV-wt animals 1768 (lane 4) and 1769 (lane 5) as well as at the time
immunized with VV-env and one immunized with VV-gag-of the second challenge (C) with the immune sera 1698 (lane 1), 1701
(lane 2), 1715 (lane 3), 1763 (lane 4), and 1769 (lane 5). Immunoprecipi- env. The majority of the animals had developed an incom-
tates were separated by SDS– PAGE and autoradiographed. plete or partial immunity and VV priming was not advanta-
geous.
This is in accordance to our results, where VV priming
rhesus monkeys as well as with the spleen homogenate was also not superior. Whereas all our O-gp130-immu-
comprising the SIVmac32H/spI. In this test, a reactivity nized animals had developed a sterilizing immunity at the
could not be detected (data not shown). Furthermore, all time of the first challenge, only one of the three animals of
immune sera at time of the first (Figs. 3A and 3B) and the VV-gp130 group and one of the two animals of the
second (Fig. 3C) challenges were tested for their reactiv- VV-wt group were completely immune. However, in two
ity with 125I-labeled gp130 oligomers used for immuniza- animals, one of the VV-gp130 group and one of the VV-
tion. Only the gp130 was recognized. wt group, an immune status not described earlier in the
The results presented above demonstrate that only the SIV system was observed. Both animals were positive
immunization with purified virion-derived gp130 oligo- only in the DNA–PCR, but negative for all other infection
mers could protect all rhesus monkeys against the ho- parameters. Obviously, the primary infection of these ani-
mologous challenge with human T-cell-grown SIV- mals could not be prevented, but later virus replication
mac32H. Priming with recombinant VV was not advanta- was effectively suppressed. In an earlier vaccine trial
geous. The majority of animals was also protected with HIV-2, a similar situation was found (14). We suggest
against the challenge with the ex vivo isolate SIV- to designate this status as silent infection. At the time of
mac32H/spI after revaccination of the protected animals the second challenge two of the five animals had devel-
half a year later. Thus, virion-derived purified envelope oped a sterilizing immunity and one of the five animals
glycoproteins in an oligomeric form can be employed a silent infection. Thus, the gp130 vaccine had also in-
successfully as a subunit vaccine against the infection duced a protective immunity against the ex vivo isolate
with SIVmac32H derived from cell culture or prepared SIVmac32H/spI in three of five animals.
ex vivo. In the SIV macaque model, a similar complete Until now, a protective immunity could not be induced
protection was only obtained with whole inactivated virus with SIV vaccines produced on human T-cell lines
(8) but not with subunit vaccines based on recombinant against a challenge with cell-free SIVmac251 propagated
or virion-derived external glycoproteins in a monomeric on monkey PBMC (8). This phenomenon was explained
form. Only a partial protection was achieved with an en- with xenoimmunization effects against cellular proteins
riched, virion-derived monomeric gp130 preparation (15), derived from human T-cells (34). Our results demon-
but not with recombinant gp130- or gp160-based subunit strated that at the time of the first challenge all immune
vaccines (16, 17). Only one group reported protection of sera recognized in addition to the gp130 a 45-kDa protein
rhesus monkeys against an SIV challenge (20). These in SIVmac32H-infected C8166 cells. This 45-kDa protein
animals were primed with VV expressing the SIV glyco- also reacted with a MAB against HLA class I, but also
protein gp160 followed by immunization with partially pu- with the antiserum of SIVmac251-infected rhesus mon-
rified gp160 expressed in insect cells. However, other key 1604. Thus, our gp130 oligomers might be contami-
authors could not confirm this result using a similar im- nated with traces of HLA class I molecules present in
munization schedule (16, 32). Recently, different subunit virions of SIVmac and HIV-1 (35). However, neither the
immune sera nor the MABs recognized such a 45-kDavaccines based on recombinant monomeric gp130 or
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